Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks To Open Slightly Higher With M&A In Focus

Tue, 22nd Apr 2014 06:41

LONDON (Alliance News) - UK stocks are set to open marginally higher Tuesday, as European markets play catch-up with Wall Street, which made gains over the long Easter weekend despite ongoing tensions in Ukraine.

Spreadbetters are indicating that the FTSE 100 will open slightly higher Tuesday, after closing on Thursday at 6,625.25 points, with CMC markets calling the index up by 28 points, and Alpari UK calling for a jump of 26 points.

US markets posted solid gains on Monday, with the S&P 500 closing up 0.3% and the DJIA closing up 0.4%, as markets appeared to shrug off the breakdown of the deal reached in Geneva for ending the ongoing crisis in Ukraine.

Russian Foreign Minister Sergei Lavrov on Monday accused Ukrainian authorities of violating the recent accord. Lavrov told reporters in Moscow that the government in Kiev has not acted to disarm illegal militants, especially the ones belonging to ultra-nationalist Right Sector.

Lavrov's remarks came a day after at least three people were killed in a shooting incident at a checkpoint manned by pro-Russian separatists near Sloviansk in eastern Ukraine.

"As long as the situation in Ukraine manages to stay contained to the occasional fire fight then market attention is likely to be more focussed on the latest company earnings reports from both side of the Atlantic," said CMC Markets chief market analyst Michael Hewson.

Tuesday's economic and corporate calendars allow a fairly quiet return from the long weekend for UK investors. But amid continued concern over stretched stock valuations, particularly in the technology sector, results due on Wednesday in the US from both Apple and Facebook are likely to be of particular market interest. Equally, in the UK on Wednesday, first quarter numbers from ARM Holdings, chip maker and supplier to Apple, will be closely watched.

Merger and acquisition activity is in focus, amid reports that US pharmaceutical giant Pfizer Inc. offered to acquire rival UK drugmaker AstraZeneca PLC for USD101 billion. The Sunday Times reported the takeover news, citing senior investment bankers and industry sources. While the offer has reportedly been rejected, the market is now anticipating an increased offer from Pfizer.

GlaxoSmithKline said Tuesday that it has signed a three-part inter-conditional transaction with Novartis AG which will see it sell off its Oncology portfolio, acquire Novartis' global Vaccines business, and create a dually-offered Consumer Healthcare business. The series of transactions by the pharmaceutical giant are said to be valued at more than USD25 billion.

The UK banks may also be in focus following a weekend report in the Financial Times that Barclays is set to wind down large parts of its commodity trading business, due to lower revenues and increased scrutiny from regulators.

In a fairly light economic calendar Tuesday, the eurozone consumer confidence survey at 1400 GMT is likely to be the highlight. Ahead of that, eurozone construction output data is due at 0900 GMT, and afterwards, US existing home sales data is due at 1400 GMT. There is no UK data scheduled.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright © 2014 Alliance News Limited. All Rights Reserved.

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.